Hyperlipidämie - Nebenwirkung von „atypischen” Neuroleptika?

 

 Buy Article Permissions and Reprints

Zusammenfassung

Nach der Markteinführung der so genannten ‚atypischen Neuroleptika’ sind eine Reihe von Berichten über erhöhte Blutfettwerte bei Patienten, die mit diesen Medikamenten behandelt wurden, veröffentlicht worden. In dieser Übersicht sollen die bisher in der Literatur beschriebenen Berichte und Studien referiert werden. Nach den bisher vorliegenden Daten ist eine Hyperlipidämie besonders bei Patienten, die mit Clozapin, Olanzapin und auch Quetiapin behandelt wurden, beobachtet worden. Es sind insbesondere starke Anstiege der Serumkonzentrationen der Triglyzeride berichtet worden. Die zugrunde liegenden Pathomechanismen sind noch nicht hinreichend geklärt. Da eine Hyperlipidämie ein wichtiger Aspekt des so genannten metabolischen Syndroms ist, das sehr häufig zu schwer wiegenden Folgeerkrankungen, v. a. Herz-/Kreislauferkrankungen, führt, sollte einer Hyperlipidämie als einer möglichen Nebenwirkung von Neuroleptika vermehrt Aufmerksamkeit gewidmet werden.

Abstract

After the introduction of the so-called ‘atypical antipsychotics’ some reports concerning hyperlipidemia observed in patients treated with these drugs have been published. The studies and case reports available up to now were reviewed. The available data show that hyperlipidemia particularly occurred in patients receiving clozapine, olanzapine and also quetiapine. Predominately elevated serum levels of triglycerides have been reported. The underlying pathomechanism still remains widely unclear. Since hyperlipidemia is an important symptom of the so called ‘metabolic syndrome’ which is often associated with severe complications like cardial and vascular diseases, more attention should be paid to hyperlipidemia as a potential side effect of antipsychotics.

Literatur

• 1 Naber D, Lambert M, Krausz M. Atypische Neuroleptika in der Behandlung schizophrener Patienten. 2. Aufl. Bremen: Uni-Med 2000
  Google Scholar
• 2 Henderson D C. Clozapine: Diabetes mellitus, weight gain, and lipid abnormalities.  J Clin Psychiatry. 2001;  62 Suppl 23 39-44
  PubMedGoogle Scholar
• 3 Kato M M, Goodnick P J. Antipsychotic medication: Effects on regulation of glucose and lipids.  Expert Opin Pharmacother. 2001;  2 1571-1582
  CrossrefPubMedGoogle Scholar
• 4 Mclntyre R S, McCann S M, Kennedy S H. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.  Can J Psychiatry. 2001;  46 273-281
  PubMedGoogle Scholar
• 5 Assmann G, Schulte H. The importance of triglycerides: results from the Prospective Cardiovascular Munster (PROCAM) Study.  Eur J Epidemiol. 1992;  8 Suppl 1 99-103
  CrossrefPubMedGoogle Scholar
• 6 Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor.  Am J Cardiol. 2000;  86 943-949
  CrossrefPubMedGoogle Scholar
• 7 Miller M. The epidemiology of triglyceride as a coronary artery disease risk factor.  Clin Cardiol. 1999;  22 (6 Suppl) II1-6
  PubMedGoogle Scholar
• 8 Laaser U. Nutzen und Kosten bei Früherkennung und Frühbehandlung der Hypercholesterinämie.  Z Kardiol. 1994;  83 Suppl 6 163-167
  PubMedGoogle Scholar
• 9 Richter W O, Richter V, Rassoul F, Sonnichsen A C, Rotzsch W, Schwandt P. Kardiovaskuläre Risikofaktoren in den alten und neuen Bundesländern.  Fortschr Med. 1993;  111 214-218
  PubMedGoogle Scholar
• 10 Spelsberg A, Weiland K, Stolpe S, Segerling M, Keil U. Bochumer Cholesterin und Blutdruckscreening-Studie 1990.  Fortschr Med. 1992;  110 387-392
  PubMedGoogle Scholar
• 11 Hershcopf R J, Elahi D, Andres R, Baldwin H L, Raizes G S, Schocken D D, Tobin J D. Longitudinal changes in serum cholesterol in man: an epidemiologic search for an etiology.  J Chronic Dis. 1982;  35 101-114
  CrossrefPubMedGoogle Scholar
• 12 McLaughlin T, Abbasi F, Lamendola C, Yeni-Komshian H, Reaven G. Carbohydrate-induced hypertriglyceridemia: an insight into the link between plasma Insulin and triglyceride concentrations.  J Clin Endocrinol Metab. 2000;  85 3085-3088
  CrossrefPubMedGoogle Scholar
• 13 Richter W O, Sonnichsen A C, Schwandt P. Results and efficacy of public screening for hypercholesterolemia: the Bavarian Cholesterol Screening Project.  J Clin Epidemiol. 1995;  48 1307-1317
  CrossrefPubMedGoogle Scholar
• 14 Ford E S, Giles W H, Dietz W H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.  JAMA. 2002;  287 356-359
  CrossrefPubMedGoogle Scholar
• 15 Wetterling T. Hyperlipidämie - Nebenwirkung bei Behandlung mit einem atypischen Neuroleptikum (Zotepin)?.  Psychiat Prax. 2002;  29 438-440
  PubMedGoogle Scholar
• 16 Koro C E, Fedder D O, Italien G J, Weiss S, Magder L S, Kreyenbuhl J, Revicki D, Buchanan R W. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.  Arch Gen Psychiatry. 2002;  59 1021-1026
  PubMedGoogle Scholar
• 17 Clark M L, Johnson P C. Amenorrhea and elevated serum cholesterol produced by tri-fluoro-methylated phenothiazine.  J Clin Endocrinol Metab. 1960;  20 641-646
  PubMedGoogle Scholar
• 18 Clark M L, Ray T S, Paredes A, Ragland R E, Costiloe J P, Smith C W, Wolf S. Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships.  Psychosom Med. 1967;  29 634-642
  PubMedGoogle Scholar
• 19 Mefferd R B, Labrosse E H, Gawienowski A M. Influence of Chlorpromazine on biochemical variables of male schizophrenics.  J Nerv Ment Dis. 1958;  127 167-179
  PubMedGoogle Scholar
• 20 Sasaki J, Funakoshi M, Arakawa K. Lipids and apolipoproteins in patients treated with major tranquillizers.  Clin Pharmacol Ther. 1985;  37 684-687
  PubMedGoogle Scholar
• 21 Lund B C, Perry P J, Brooks J M, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach.  Arch Gen Psychiatry. 2001;  58 1172-1176
  PubMedGoogle Scholar
• 22 Ghaeli P, Dufresne R L. Serum triglyceride levels in patients treated with clozapine.  Am J Health Sys Pharm. 1996;  53 2079-2081
  PubMedGoogle Scholar
• 23 Spivak B, Roitman S, Vered Y, Mester R, Graff E, Talmon Y, Guy N, Gonen N, Weizman A. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine.  Clin Neuropharmacol. 1998;  21 245-250
  PubMedGoogle Scholar
• 24 Gaulin B D, Markowitz J S, Caley C F, Nesbitt L A, Dufresne R L. Clozapine-associated elevation in triglycerides.  Am J Psychiatry. 1999;  156 1270-1272
  PubMedGoogle Scholar
• 25 Wirshing D A. Adverse effects of atypical antipsychotics.  J Clin Psychiatry. 2001;  62 Suppl 21 7-10
  PubMedGoogle Scholar
• 26 Braun G A, Paulois M E. Sterol metabolism: biochemical differences among butyrophenons.  Int J Neuropsychiatry. 1967;  3 Suppl 26-27
  PubMedGoogle Scholar
• 27 Clark M L, Braun G A, Hewson J R, Serafetinides E A, Colmore J P, Rahhai D K. Trifluoperidol and cholesterol in man.  Clin Pharmacol Ther. 1968;  9 333-340
  PubMedGoogle Scholar
• 28 Serafetinides E A, Colmore J P, Rahhai D K, Clark M L. Trifluoperidol in chronic male psychiatric patients.  Behav Neuropsychiaty. 1971;  3 10-12
  PubMedGoogle Scholar
• 29 Simpson G M, Cooper T B. The effect of three butyrophenones on serum cholesterol levels.  Curr Ther Res Clin Exp. 1966;  8 249-255
  PubMedGoogle Scholar
• 30 Simpson G M, Cooper T B, Braun G A. Further studies on the effect of butyrophenons on cholesterol synthesis in humans.  Curr Ther Res Clin Exp. 1967;  9 413-418
  PubMedGoogle Scholar
• 31 Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients.  Clin Pharmacol Ther. 1970;  11 883-889
  PubMedGoogle Scholar
• 32 Sasaki J, Kumagae G, Sata T, Kuramitsu M, Arakawa K. Decreased concentration of high density lipoprotein cholesterol in schizophrenics treated with phenothiazines.  Atherosclerosis. 1984;  51 163-169
  PubMedGoogle Scholar
• 33 Spivak B, Lamschtein C, Talmon Y, Guy N, Mester R, Feinberg l, Kotler M, Weizman A. The impact on serum lipids of clozapine treatment in chronic schizophrenic patients.  Clin Neuropharmacol. 1999;  2 98-101
  PubMedGoogle Scholar
• 34 Meyer J M. A rectrospective comparison of weight, lipid, and glucose changes between olanzapine- and risperidone-treated inpatients: metabolic outcomes after 1 year.  J Clin Psychiatry. 2002;  63 425-433
  PubMedGoogle Scholar
• 35 Simpson G, Romano S J, Horne R L. et al .Ziprasidone versus olanzapine in schizophrenia: Result of a double-blind study. New Orleans: American Psychiatric Association Annual Meeting, NR 252 2001: 68-69 (zitiert nach 3)
  Google Scholar
• 36 Dursun S M, Szemis A, Andrews H, Reveley M A. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study.  J Psychiatry Neurosci. 1999;  24 453-455
  PubMedGoogle Scholar
• 37 Henderson D C, Cagliero E, Gray C, Nasrallah R A, Hayden D L, Schoenfeld D A, Goff D C. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.  Am J Psychiatry. 2000;  157 975-981
  CrossrefPubMedGoogle Scholar
• 38 Leonard P, Halley A, Browne S. Prevalence of obesity, lipid and glucose abnormalities in outpatients prescribed clozapine.  Ir Med J. 2002;  95 119-120
  PubMedGoogle Scholar
• 39 Meyer J M. Novel antipsychotics and severe hyperlipidemia.  J Clin Psychopharmacol. 2001;  21 369-374
  CrossrefPubMedGoogle Scholar
• 40 Melkersson K l, Hulting A L, Brismar K E. Elevated levels of Insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.  J Clin Psychiatry. 2000;  61 742-749
  PubMedGoogle Scholar
• 41 Osser D N, Najarian D M, Dufresne R L. Olanzapine increases weight and serum triglyceride levels.  J Clin Psychiatry. 1999;  60 767-770
  PubMedGoogle Scholar
• 42 Sheitman B B, Bird P M, Binz W, Akinli L, Sanchez C. Olanzapine-induced elevation of plasma triglyceride levels.  Am J Psychiatry. 1999;  156 1471-1472
  PubMedGoogle Scholar
• 43 Kinon B J, Basson B R, Gilmore J A, Tollefson G D. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.  J Clin Psychiatry. 2001;  62 92-100
  PubMedGoogle Scholar
• 44 Daniel D G, Zimbroff D L, Potkin S G, Reeves K R, Harrigan E P, Lakshminarayanan M I. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.  Neuropsychopharmacology. 1999;  20 491-505
  CrossrefPubMedGoogle Scholar
• 45 Keck Jr P, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan E P, Morrissey M R. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.  Psychopharmacology. 1998;  140 173-184
  CrossrefPubMedGoogle Scholar
• 46 Kingsbury S J, Fayek M, Trufasiu D, Zada J, Simpson G M. The effects of Ziprasidone on cholesterol, triglycerides and glucose.  J Clin Psychiatry. 2001;  62 347-349
  PubMedGoogle Scholar
• 47 Romano S J, Cutler N, Weiden P J, Simpson G M. Ziprasidone's effects on weight and lipids in patients with schizophrenia. Montreal: Poster, 23th Congress 23. - 27. 6. 2002
  Google Scholar
• 48 Wetterling T. Gewichtszunahme - eine unterschätzte Nebenwirkung atypischer Neuroleptika?.  Fortschr Neurol Psychiat. 2000;  68 546-556
  PubMedGoogle Scholar
• 49 Brown C D, Higgins M, Donato K A, Rohde F C, Garrison R, Obarzanek E, Ernst N D, Horan M. Body mass index and the prevalence of hypertension and dyslipidemia.  Obes Res. 2000;  8 605-619
  CrossrefPubMedGoogle Scholar
• 50 Denke M A, Sempos C T, Grundy S M. Excess body weight. An underrecognized contributor to high blood cholesterol levels in white American men.  Arch Intern Med. 1993;  153 1093-1103
  CrossrefPubMedGoogle Scholar
• 51 Denke M A, Sempos C T, Grundy S M. Excess body weight. An underrecognized contributor to dyslipidemia in white American women.  Arch Intern Med. 1994;  154 401-410
  CrossrefPubMedGoogle Scholar
• 52 Thune l, Njolstad l, Lochen M L, Forde O H. Physical activity improves the metabolic risk profiles in men and women: the Tromsö Study.  Arch Intern Med. 1998;  158 1633-1640
  CrossrefPubMedGoogle Scholar
• 53 Ferreira M F, Sobrinho L G, Santos M A, Sousa M F, Uvnas-Moberg K. Rapid weight gain, at least in some women, is an expression of a neuroendocrine state characterized by reduced hypothalamic dopaminergic tone.  Psychoneuroendocrinol. 1998;  23 1005-1013
  PubMedGoogle Scholar
• 54 Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels.  Clin Endocrinol. 1998;  48 547-553
  CrossrefPubMedGoogle Scholar
• 55 Bapista T, Lacruz A, Mendoza S de, Mendoza Guilleri J M, Silvera A, Angeles F, Mendoza M T, Hernandez L. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones.  Pharmacopsychiatry. 2000;  33 81-88
  Article in Thieme ConnectPubMedGoogle Scholar
• 56 Brömel T, Blum W F, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, Krieg J-C, Hebebrand J. Serum leptin levels increase rapidly after initiation of clozapine therapy.  Mol Psychiatry. 1998;  3 76-80
  CrossrefPubMedGoogle Scholar
• 57 Kraus T, Zimmermann U, Schuld A, Haack M, Hinze-Selch D, Pollmächer T. Zur Pathophysiologie der Gewichtsregulation im Rahmen der Therapie mit Psychopharmaka.  Fortschr Neurol Psychiat. 2001;  69 116-137
  Article in Thieme ConnectPubMedGoogle Scholar
• 58 Kametani T, Koshida H, Nagaoka T, Miyakoshi H. Hypertriglyceridemia is an independent risk factor for development of impaired fasting glucose and diabetes mellitus: a 9-year longitudinal study in Japanese.  Intern Med. 2002;  41 516-521
  PubMedGoogle Scholar
• 59 McLaughlin T, Abbasi F, Lamendola C, Yeni-Komshian H, Reaven G. Carbohydrate-induced hypertriglyceridemia: an insight into the link between plasma insulin and triglyceride concentrations.  J Clin Endocrinol Metab. 2000;  85 3085-3088
  CrossrefPubMedGoogle Scholar
• 60 Wetterling T. Diabetes mellitus Typ II - induziert durch atypische Neuroleptika?. Fortschr Neurol Psychiat 2003: 71 (in Druck)
  Google Scholar

Prof. Dr. Tilman Wetterling

Klinik für Psychiatrie und Psychotherapie - Gerontopsychiatrie · Vivantes Klinikum Hellersdorf

Myslowitzer Str. 45

12621 Berlin

Email: t.wetterling@kh-hellersdorf.de